The Clorox Company (CLX) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
9 Jan, 2026Executive summary
Leadership transition announced: Kevin Jacobsen retiring as CFO, Luc Bellet to assume the role April 1st, ensuring continuity in financial strategy and transformation initiatives.
Q2 FY2025 net sales declined 15% to $1.69B, reflecting lapping of post-cyberattack recovery and divestitures; organic sales down 9%.
Diluted EPS rose 105% to $1.54, driven by lapping prior-year charges and cyberattack insurance recoveries; adjusted EPS fell 28% to $1.55.
Company has navigated significant disruptions in recent years, including pandemic-driven demand, inflation, and a cyber attack, while maintaining strong compounded annual sales growth and rebuilding gross margin.
Clorox and P&G will end the Glad joint venture in Jan 2026; Clorox to acquire P&G's 20% stake at fair market value.
Financial highlights
Q2 organic sales declined 9.5% year-over-year, outperforming guidance due to stronger category performance and share gains; Kingsford shipment timing contributed less than one point to the quarter.
Gross margin expanded 30 bps to 43.8%, supported by cost savings and divestitures, partially offset by higher costs.
Q2 net earnings: $194M, up from $96M a year ago; adjusted EBIT for Q2 was $258M, down 33% year-over-year.
Free cash flow is expected to land at the low end of the 11%-13% target range due to ERP-related inventory build, but operationally is closer to 13%.
Net cash from operations for six months: $401M, up 132%.
Outlook and guidance
FY2025 net sales expected to be down 1% to up 2%, including 1–2 pts benefit from ERP transition shipments.
Organic sales expected up 4–7%, excluding negative impacts from Argentina and VMS divestitures.
Gross margin now expected to rise 125–150 bps for FY2025.
FY2025 diluted EPS forecast raised to $5.52–$5.92 (up 145–163% YoY); adjusted EPS to $6.95–$7.35 (up 13–19%).
Long-term algorithm of 3%-5% annual growth reaffirmed, contingent on macro environment improvement and category normalization.
Latest events from The Clorox Company
- ERP completion, innovation, and GOJO acquisition drive growth and margin expansion plans.CLX
Citi’s 2026 Global Consumer & Retail Conference 20269 Mar 2026 - Digital and portfolio advances, plus GOJO acquisition, drive growth and health & hygiene scale.CLX
Consumer Analyst Group of New York Conference (CAGNY) 202619 Feb 2026 - Q2 sales and EPS fell; GOJO deal and innovation aim to offset ongoing cost and market headwinds.CLX
Q2 20263 Feb 2026 - ERP-driven margin and EPS gains in FY25 reverse in FY26, with innovation to support recovery.CLX
Q4 20253 Feb 2026 - Margin expansion and portfolio reshaping drive FY24 results and FY25 outlook.CLX
Q4 20242 Feb 2026 - Recovery, margin growth, and digital innovation drive strong outlook post-cyberattack.CLX
2024 dbAccess Global Consumer Conference31 Jan 2026 - $2.25B acquisition expands health & hygiene leadership, with $50M+ in synergies expected.CLX
M&A announcement22 Jan 2026 - Recovery, portfolio shifts, and digital upgrades set the stage for renewed growth in 2025.CLX
Barclays 17th Annual Global Consumer Staples Conference22 Jan 2026 - Sales and margins rebounded, with EPS up 371% and FY25 outlook raised post-cyberattack.CLX
Q1 202517 Jan 2026